Immix Biopharma, Inc.
IMMX · NASDAQ
Bulios Fair Price
$9.91
18.4% downside
Current Price
$12.14
According to Bulios Fair Price, IMMX is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
About the company
Immix Biopharma, Inc. is a biotechnology company focused on researching and developing novel therapeutic treatments in the field of cancer immunotherapy. Their main focus is on harnessing the body's immune system to fight cancer through innovative treatment approaches, such as antigen-specific T-cell therapies. The company is developing and testing new therapeutic agents aimed at improving treatment efficacy and reducing side effects in patients with various types of cancer. Their research aims to identify and target specific molecules and processes that are crucial for immune response and regulatory mechanisms in combating cancerous diseases. Shares of Immix Biopharma, Inc. may be of interest to investors following innovations in cancer treatment and seeking investment opportunities in the biotechnology sector.
Sector
Healthcare
Industry
Biotechnology
CEO
Ilya Rachman
Employees
21
Headquarters
Los Angeles
Upcoming events
Earnings
Upcoming earnings report